Mutations affecting the sensitivity of the influenza virus neuraminidase to 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid.

4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid (4-guanidino-Neu5Ac2en) specifically inhibits the influenza virus neuraminidase (NA) through interaction of the guanidino group with conserved Glu 119 and Glu 227 residues in the substrate binding pocket of the enzyme. To understand the mechanism by which influenza viruses become resistant to 4-guanidino-Neu5Ac2en, we investigated mutations at amino acid residues 119 and 227 in the influenza virus NA for their effects on this compound and on NA activity. The NA gene was cloned from the NWS-G70c virus, and mutations were introduced at the codon for amino acid residue 119 or 227. All of the 13 mutants containing a change at residue 119 were transported to the cell surface, although their expression levels ranged from 68.2 to 91.3% of wild type. Mutant NAs that retained at least 20% of the wild-type enzymatic activity were tested for their sensitivity to 4-guanidino-Neu5Ac2en and found to be sevenfold less sensitive to this compound than was the wild-type NA. By contrast, only 6 of 13 mutants defined by modifications at residue 227 were transported to the cell surface, and those NAs lacked substantial enzymatic activity (9% of wild type, at most). These results suggest that only a limited number of resistant viruses arise through mutations at Glu 119 and Glu 227 under selective pressure from 4-guanidino-Neu5Ac2en and that the development of compounds which interact with 227 Glu more strongly than does 4-guanidino-Neu5Ac2en may reduce the likelihood of drug-resistant viruses still further.

[1]  G L Ada,et al.  Options for the control of influenza III. Cairns, North Queensland, Australia (4-9 May 1996). , 1997, Vaccine.

[2]  P. Colman,et al.  Mutation in the influenza virus neuraminidase gene resulting in decreased sensitivity to the neuraminidase inhibitor 4-guanidino-Neu5Ac2en leads to instability of the enzyme. , 1996, Virology.

[3]  R. Webster,et al.  Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en , 1996, Journal of virology.

[4]  L. Mitnaul,et al.  The cytoplasmic tail of influenza A virus neuraminidase (NA) affects NA incorporation into virions, virion morphology, and virulence in mice but is not essential for virus replication , 1996, Journal of virology.

[5]  F. Hayden,et al.  Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. , 1996, JAMA.

[6]  R. Bethell,et al.  Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en , 1996, Antimicrobial agents and chemotherapy.

[7]  P. Colman,et al.  Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en. , 1995, Virology.

[8]  G. Air,et al.  Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en. , 1995, Virology.

[9]  D. M. Ryan,et al.  GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets , 1995, Antimicrobial agents and chemotherapy.

[10]  R. Webster,et al.  Inhibition of replication of avian influenza viruses by the neuraminidase inhibitor 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid. , 1995, Virology.

[11]  P. Colman,et al.  Three‐dimensional structure of the complex of 4‐guanidino‐Neu5Ac2en and influenza virus neuraminidase , 1995, Protein science : a publication of the Protein Society.

[12]  D. M. Ryan,et al.  Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase) , 1994, Antimicrobial Agents and Chemotherapy.

[13]  T H Jukes,et al.  Rates of transition and transversion in coding sequences since the human-rodent divergence. , 1994, Genomics.

[14]  W G Laver,et al.  Three-dimensional structure of influenza A N9 neuraminidase and its complex with the inhibitor 2-deoxy 2,3-dehydro-N-acetyl neuraminic acid. , 1994, Journal of molecular biology.

[15]  D. M. Ryan,et al.  4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro , 1993, Antimicrobial Agents and Chemotherapy.

[16]  D. M. Ryan,et al.  Rational design of potent sialidase-based inhibitors of influenza virus replication , 1993, Nature.

[17]  R. Webster,et al.  Phylogenetic analysis of the N8 neuraminidase gene of influenza A viruses. , 1993, Virology.

[18]  Yamamura Ken-ichi,et al.  Efficient selection for high-expression transfectants with a novel eukaryotic vector , 1991 .

[19]  H. Niwa,et al.  Efficient selection for high-expression transfectants with a novel eukaryotic vector. , 1991, Gene.

[20]  T. Hopp,et al.  A calcium-dependent antibody for identification and purification of recombinant proteins. , 1989, BioTechniques.

[21]  K. Mullis,et al.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. , 1988, Science.

[22]  G. Air,et al.  Site-directed mutation of the active site of influenza neuraminidase and implications for the catalytic mechanism. , 1987, Biochemistry.

[23]  J. Miller,et al.  Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system , 1987, Molecular and cellular biology.

[24]  G. Air,et al.  Three‐dimensional structure of neuraminidase of subtype N9 from an avian influenza virus , 1987, Proteins.

[25]  D. Nayak,et al.  Identification of defects in the neuraminidase gene of four temperature-sensitive mutants of A/WSN/33 influenza virus. , 1986, Virology.

[26]  G. Air,et al.  Loss of enzyme activity in a site-directed mutant of influenza neuraminidase compared to expressed wild-type protein. , 1986, Virology.

[27]  G. Air,et al.  Gene and protein sequence of an influenza neuraminidase with hemagglutinin activity. , 1985, Virology.

[28]  J. N. Varghese,et al.  Structure of the catalytic and antigenic sites in influenza virus neuraminidase , 1983, Nature.

[29]  J. N. Varghese,et al.  Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 Å resolution , 1983, Nature.

[30]  D. Nayak,et al.  Complete nucleotide sequence of the neuraminidase gene of human influenza virus A/WSN/33 , 1982, Journal of virology.

[31]  S. Fields,et al.  Structure of the neuraminidase gene in human influenza virus A/PR/8/34 , 1981, Nature.

[32]  W. J. Bean,et al.  Electrophoretic analysis of iodine-labeled influenza virus RNA segments. , 1980, Analytical biochemistry.

[33]  T. Warner,et al.  Synthesis of 2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid and detection of skin fibroblast neuraminidase in normal humans and in sialidosis. , 1979, Biochemistry.

[34]  R. Compans,et al.  Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. , 1974, Virology.

[35]  P. Palese,et al.  Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid. , 1974, Virology.

[36]  L. Reed,et al.  A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .